

Safety and performance of trehalose hyaluronic acid versus standard infiltrative therapy based on medium weight sodium hyaluronate in knee joint osteoarthritis treatment

Submission date 09/09/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 30/09/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 09/11/2023	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Knee osteoarthritis is a disease affecting the knee joint that gets worse over time. It can lead to stiffness and swelling of the knee and can cause pain. Hyaluronic acid is used as a treatment for patients with knee osteoarthritis that continues to cause pain after standard treatment. This study intends to study a new version of hyaluronic acid. Trehalose is a chemical used to stabilize the composition of many pills and eye drops. Recently, there have been laboratory studies that show that trehalose helps hyaluronic acid remain stable and is safe and approved by the FDA when used with hyaluronic acid. This means that it, in combination with trehalose, hyaluronic acid does not break down as quickly, so could last for longer in the body, and provide pain relief for a longer period of time.

Who can participate?

Adults aged 21 years old and older with persistent knee pain due to osteoarthritis that has not been reduced with standard therapy (medicine, rehabilitation, and rest) for 6 months.

What does the study involve?

Participants will be allocated to one of two groups, with an equal chance of being in either group (like tossing a coin). Participants and researchers will not have a choice in the treatment given. In one group the patients will be injected in the knee with the standard hyaluronic acid. In the other group, patients will be injected with hyaluronic acid with added trehalose. Participants will not know which treatment they have received during the study and neither will the doctors administering their treatment.

What are the possible benefits and risks of participating?

It is hoped that a benefit of participating will be that patients are able to achieve longer-lasting results of pain relief or pain reduction if combined with trehalose. This product is safe, so no adverse reactions are expected.

Where is the study run from?
OASI Bioresearch Foundation (Italy)

When is the study starting and how long is it expected to run for?
From February 2019 to October 2021

Who is funding the study?
OASI Bioresearch Foundation (Italy)

Who is the main contact?
Macarena Morales
maquismoralis@hotmail.com

Contact information

Type(s)
Scientific

Contact name
Dr Macarena Morales

ORCID ID
<http://orcid.org/0000-0003-1483-9870>

Contact details
Via Amadeo G.A 24 1-2
Milano
Italy
20133
+34 (0)673780061
maquismoralis@hotmail.com

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
Nil known

Study information

Scientific Title

Efficacy evaluation of trehalose-hyaluronic acid versus non-trehalose hyaluronic acid in persistent symptomatic knee osteoarthritis patients, with outcome measurement comparison of KOOS, IKDC, and VAS score at basal, 3 and 6 months

Study objectives

It is hypothesized that in vivo trehalose-hyaluronic acid (T-HA) has longer-lasting clinical results than non-trehalose hyaluronic acid (NT-HA) when applied as an injectable formula for osteoarthritis (OA) symptomatic knees.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 01/05/2019, OASI Institutional review board (via GA Amadeo Milano 20133 Italy; +39 (0)270124931; info@oasiortopedia.it), ref: not applicable

Study design

Single-centre prospective double-blinded randomized control trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

GP practice

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Osteoarthritis of the knee

Interventions

Participants are randomized with an allocation ratio of 1:1 to receive either T-HA or NT-HA. The manufacturer provided the products labelled as A or B (corresponding to group A or B, respectively). Both products had the same syringe, color (transparent), texture, and quantity (2 ml). In this way, the study was blinded for patients, clinicians, researchers, and the manufacturer who handled the product. The nature of the product was revealed only when the study was finished. Each patient received three doses separated within 15 days.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Hyaluronic acid

Primary outcome measure

Treatment performance measured using the Knee Injury and Osteoarthritis Outcome Score (KOOS), International Knee Documentation Committee (IKDC), and Visual Analogue Scale (VAS) at baseline, 3, and 6 months

Secondary outcome measures

Safety measured using adverse reactions recorded for the duration of the trial

Overall study start date

01/02/2019

Completion date

01/10/2021

Eligibility

Key inclusion criteria

1. Aged 18 to 80 years
2. Symptomatic knee osteoarthritis, grade I to III according to Kellgren and Lawrence classification
3. Without pain relief after at least 3 months of non-invasive treatment
4. Osteoarthritis diagnosed by x-ray and classified according to Kellgren and Lawrence classification

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

80 Years

Sex

Both

Target number of participants

60 in total, 30 per arm

Total final enrolment

60

Key exclusion criteria

1. Any recent intra-articular injection therapy
2. Knee instability
3. Significant axial deviation
4. Systemic disorders such as rheumatoid arthritis, coagulopathies, or infections

Date of first enrolment

01/06/2019

Date of final enrolment

01/04/2021

Locations**Countries of recruitment**

Italy

Study participating centre

OASI Bioresearch Foundation

via Amadeo GA 24 1-2

Milano

Italy

20133

Sponsor information**Organisation**

OASI Bioresearch Foundation

Sponsor details

Via Amadeo G.A 24 1-2

Milano

Italy

20133

+39 (0)270124931

agobbi@oasiortopedia.it

Sponsor type

Research organisation

Website

<https://www.gobbicartilagedoctor.com/en/about-us/dr-alberto-gobbi/>

ROR

<https://ror.org/048qh2s42>

Funder(s)

Funder type

Research organisation

Funder Name

OASI Bioresearch Foundation

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

10/09/2021

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from fellow@oasiortopedia.it.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/09/2022	09/11/2023	Yes	No